Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 6 de 6
1.
Metab Brain Dis ; 32(2): 307-310, 2017 04.
Article En | MEDLINE | ID: mdl-28130616

Canavan's disease (CD) is a hereditary leukodystrophy caused by mutations in the aspartoacylase gene (ASPA), leading to spongiform degeneration of the white matter and severe impairment of psychomotor development. We present the cases of two non-Jewish sisters with CD that have a milder and protracted clinical course compared to typical CD. MRI imaging revealed bilateral high-signal-intensity areas in the thalami and the internal capsule and MR spectroscopy showed typical findings for CD (a marked increase in N-acetylaspartate (NAA) levels). FA values of the right and left corticospinal tracts at the level of the posterior limb of the internal capsule, and the centrum semiovale were found to be significantly reduced compared to healthy controls. From a neurophysiological point of view, the peripheral motor system was normal. In contrast, cortical stimulation at maximal intensity failed to elicit facilitated or resting MEPs and silent periods (SPs) in upper and lower limbs, providing evidence for significant upper motor pathway dysfunction.


Canavan Disease/diagnostic imaging , Canavan Disease/therapy , Diffusion Tensor Imaging/methods , Efferent Pathways/diagnostic imaging , Transcranial Magnetic Stimulation/methods , Adult , Aspartic Acid/analogs & derivatives , Aspartic Acid/metabolism , Evoked Potentials, Motor , Female , Humans , Internal Capsule/diagnostic imaging , Pyramidal Tracts/diagnostic imaging , Pyramidal Tracts/metabolism , Siblings , Thalamus/diagnostic imaging
2.
J Neurol ; 263(12): 2386-2394, 2016 Dec.
Article En | MEDLINE | ID: mdl-27604619

A first seizure is a life-changing event with physical and psychological consequences. We aimed to assess the role of early comprehensive patient care after a first unprovoked seizure to improve diagnostic accuracy and follow-up adherence. From April 2011 to March 2012, patients presenting a first unprovoked epileptic seizure received standard patient care (SPC), i.e., a consultation in the ED, an EEG and a CT scan. The patients were notified of the follow-ups. We compared this protocol to subsequently acquired "early comprehensive patient care" (ECPC), which included a consultation by an epileptologist in the emergency department (ED), a routine or long-term monitoring electroencephalogram (LTM-EEG), magnetic resonance imaging and three follow-up consultations (3 weeks, 3 months, 12 months). 183 patients were included (113 ECPC, 70 SPC). LTM-EEG and MRI were performed in 51 and 85 %, respectively, of the patients in the ECPC group vs in 7 and 52 % of the patients in the SPC group (p < 0.001). A final diagnosis was obtained in 64 vs 43 % of the patients in the ECPC vs SPC group (p < 0.01). Patient attendance at 3-month was 84 % in the ECPC group vs 44 % in the SPC group (p < 0.001). At 12-month follow-up, the delay until the first recurrence was longer in the ECPC group (p = 0.008). An early epileptologist-driven protocol is associated with clinical benefit in terms of diagnostic accuracy, follow-up adherence and recurrence. This study highlights the need for epilepsy experts in the early assessment of a first epileptic seizure, starting already in the ED.


Disease Management , Epilepsy/diagnosis , Epilepsy/therapy , Adolescent , Adult , Aged , Brain/diagnostic imaging , Brain/physiopathology , Costs and Cost Analysis , Electrocardiography , Electroencephalography , Epilepsy/economics , Epilepsy/psychology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neuroimaging , Retrospective Studies , Young Adult
6.
Mult Scler ; 14(2): 278-83, 2008 Mar.
Article En | MEDLINE | ID: mdl-17942513

Malignant multiple sclerosis (MS) is a rare but clinically important subtype of MS characterized by the rapid development of significant disability in the early stages of the disease process. These patients are refractory to conventional immunomodulatory agents and the mainstay of their treatment is plasmapheresis or immunosuppression with mitoxantrone, cyclophosphamide, cladribine or, lately, bone marrow transplantation. We report on the case of a 17-year old patient with malignant MS who was treated with high-dose chemotherapy plus anti-thymocyte globulin followed by autologous stem cell transplantation. This intervention resulted in an impressive and long-lasting clinical and radiological response. It is concluded that intensive immunosuppression followed by autologous stem cell transplantation is a viable therapeutic option in patients with malignant MS unresponsive to conventional forms of treatment.


Multiple Sclerosis/therapy , Recovery of Function , Stem Cell Transplantation , Adolescent , Antilymphocyte Serum/therapeutic use , Combined Modality Therapy , Humans , Immunosuppressive Agents/therapeutic use , Magnetic Resonance Imaging , Male , Multiple Sclerosis/drug therapy , Multiple Sclerosis/pathology , Transplantation, Autologous
...